首页 | 本学科首页   官方微博 | 高级检索  
检索        

扶正通络消积三方分期治疗肺纤维化大鼠疗效评价
引用本文:李建生,陈龙飞,李亚,田燕歌,冀会鸽,刘冠汝,郭闪闪,卢灵灵,何慧慧,贾瑞.扶正通络消积三方分期治疗肺纤维化大鼠疗效评价[J].中华中医药杂志,2021(3):1671-1676.
作者姓名:李建生  陈龙飞  李亚  田燕歌  冀会鸽  刘冠汝  郭闪闪  卢灵灵  何慧慧  贾瑞
作者单位:河南中医药大学;河南中医药大学;河南中医药大学第一附属医院
基金项目:国家自然科学基金项目(No.81673942,No.81673775)
摘    要:目的:观察扶正通络消积三方(养清抗纤方、保肺化纤方、金水缓纤方)在肺纤维化大鼠不同时期的疗效。方法:180只SD大鼠分为空白组、模型组、吡啡尼酮组、养清抗纤组、保肺化纤组、金水缓纤组,每组30只(每个时间点10只)。建立肺纤维化大鼠模型,各组大鼠于造模后第1~13天、15~27天、29~41天采用相应的药物灌胃后,分别于第14、28、42天取材。观察大鼠肺功能、肺组织病理、肺组织羟脯氨酸(HYP)、α-平滑肌肌动蛋白(α-SMA),支气管肺泡灌洗液(BALF)中肿瘤坏死因子-α(TNF-α)、白介素(IL)-6、IL-13及血清内转化生长因子-β1(TGF-β1)、α-SMA等。采用R值综合评价法进行综合评价。结果:养清抗纤方在各个时间点均能减轻炎症,在第14天较为显著,降低IL-6、IL-1β优于吡啡尼酮(P<0.01,P<0.05),保肺化纤方和金水缓纤方在第28、42天改善纤维化程度,其综合评价R值低于吡啡尼酮(P<0.01)。结论:三方可在肺纤维化的不同时期改善大鼠肺功能、减轻炎症、改善纤维化程度,养清抗纤方、保肺化纤方、金水缓纤方分别在早、中、晚期疗效较好。

关 键 词:肺纤维化  扶正通络消积三方  分期治疗  疗效评价  养清抗纤方  保肺化纤方  金水缓纤方  炎症

Therapeutic evaluation of three formula of Fuzheng Tongluo Xiaoji in rats with pulmonary fibrosis by stages
LI Jian-sheng,CHEN Long-fei,LI Ya,TIAN Yan-ge,JI Hui-ge,LIU Guan-ru,GUO Shan-shan,LU Ling-ling,HE Hui-hui,JIA Rui.Therapeutic evaluation of three formula of Fuzheng Tongluo Xiaoji in rats with pulmonary fibrosis by stages[J].China Journal of Traditional Chinese Medicine and Pharmacy,2021(3):1671-1676.
Authors:LI Jian-sheng  CHEN Long-fei  LI Ya  TIAN Yan-ge  JI Hui-ge  LIU Guan-ru  GUO Shan-shan  LU Ling-ling  HE Hui-hui  JIA Rui
Institution:(Henan Key Laboratory of Chinese Medicine for Respiratory Disease,Henan University of Chinese Medicine,Zhengzhou 450046,China;Co-constructive Collaborative Innovation Center for Chinese Medicine and Respiratory Diseases by Henan and Ministry or Education of the Peopled Republic of China,Henan University of Chinese Medicine,Zhengzhou 450046,China;The First Affiliated Hospital of Henan University of CM,Zhengzhou 450000,China)
Abstract:Objective: To observe the efficacy of the three formula of Fuzheng Tongluo Xiaoji(Yangqing Kangxian Formula, Baofei Huaxian Formula and Jinshui Huanxian Formula) in the treatment of pulmonary fibrosis in rats. Methods: A total of 180 rats were randomly divided into normal group, model group, pirfenidone group, Yangqing Kangxian(YQKX) group, Baofei Huaxian(BFHX) group and Jinshui Huanxian(JSHX) group, with 30 rats in each group(10 rats at each time point). Rats in each group were treated with the corresponding drugs on the day 1 to 13, day15 to 27, and day 29 to 41 after modeling, the rats were sacrificed and the samples were taken on day 14, 28 and 42. Lung function, pulmonary pathology were measured;hydroxyproline(HYP) and α-smooth muscle actin(α-SMA) in lung tissue, tumor necrosis factor-α(TNF-α), interleukin(IL)-6, IL-1β, IL-13 in alveolar lavage fluid(BALF), as well as transforming growth factor-β1(TGF-β1) and α-SMA in serum were detected. The comprehensive effect evaluation was carried out by the R value comprehensive evaluation method. Results: Compared with the model group, YQKX could alleviate inflammation reaction in each time point, especially on day 14, and was better than pirfenidone in decreasing the level of IL-6 and IL-10(P<0.01, P<0.05). BFHX and JSHX could alleviate the severity of fibrosis on the 28 th and 42 th days, the R value were lower than that of pirfenidone(P<0.01). Conclusion: Three formula of Fuzheng Tongluo Xiaoji can alleviate lung function, inflammation and fibrosis in rats with pulmonary fibrosis. The effect of Yangqing Kangxian Formula, Baofei Huaxian Formula and Jinshui Huanxian Formula is better in the early, middle and late periods of the disease, respectively.
Keywords:Pulmonary fibrosis  Three formula of Fuzheng Tongluo Xiaoji  Stage therapeutics  Therapeutic evaluation  Yangqing Kangxian Formula  Baofei Huaxian Formula  Jinshui Huaxian Formula  Inflammation
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号